Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2022

View Archived Issues

New free fatty acid receptor 1 agonists identified at Rezubio Pharmaceuticals

Shanghai Zheye Biotechnology describes new anticancer compounds

Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical patent TLR7/8/9 antagonists

Apoptosis regulator Bcl-2 inhibitors discovered at Beijing Innocare Medical Technology

China Hinye Pharmaceutical presents prodrugs of the active metabolite of clopidogrel

Mouse model of SARS-CoV-2 infection shows COVID-19-like disease is dependent on ACE2

STING signaling in beta cells maintains glucose homeostasis

Type II interferon restricts severity of NMO in a new preclinical model

Bryostatin-1 promotes regenerative phenotype within microglia and CNS macrophages

Novel murine model developed to test CNS-penetrant BTK inhibitors

BAFF biomarker tied to severity of allergic rhinitis

Shionogi and Ube collaborate to advance S-337395 toward clinic for RSV

Study identifies potential new bone disease target

Murine model reveals aging to promote autoimmune encephalomyelitis with meningeal inflammation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...